Information Provided By: 
Fly News Breaks for April 10, 2015
KYTH
Apr 10, 2015 | 11:47 EDT
BofA/Merrill this morning reinstated coverage of KYTHERA Biopharmaceuticals with a Buy rating and $66 price target. The firm believes the company's ATX-101 has "significant" sales potential for the treatment of double chin. If approved, ATX-101 will be the first drug indicated for double chin, BofA/Merrill noted, and the first minimally invasive option for patients to reduce chin size. Shares of KYTHERA are up $1.87 to $48.87 in midday trading.
News For KYTH From the Last 2 Days
There are no results for your query KYTH
